The Effect of Co-Administration of Rebamipide on the Expression of Serum Gastrin in Long-term Proton Pump Inhibitor Users: A Prospective Pilot Study
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
;
: 34-37, 2012.
Article
in Korean
| WPRIM
| ID: wpr-124164
ABSTRACT
BACKGROUND/AIMS:
In one animal study, co-administration of rebamipide with proton pump inhibitors (PPIs) could suppress hypergastrinemia but there have been no such reports on humans. The aim of this study was to evaluate whether rebamipide could prevent hypergastrinemia in long-term PPI users. MATERIALS ANDMETHODS:
Patients who were diagnosed with reflux esophagitis endoscopically were enrolled in this study. In the control group, lansoprazole 30 mg was administered for 8 weeks and in the rebamipide group, lansoprazole 30 mg with rebamipide 300 mg was administered for 8 weeks. Serum gastrin level was checked before and after administration of the drugs.RESULTS:
Thirty patients were enrolled in this study. The control group included 17 patients and the rebamipide group included 13 patients. The gastrin level was elevated in the control group (28.4 pg/mL) compared to the rebamipide group (38.5 pg/mL). However, the gastrin level was decreased in 3 patients in the rebamipide group (23.1%) compared to 2 patients in the control group (11.8%).CONCLUSIONS:
Not all patients who are taking PPIs develop hypergastrinemia. Co-administration of rebamipide with PPI does not affect the serum gastrin level.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Protons
/
Gastrins
/
Esophagitis, Peptic
/
Pilot Projects
/
Prospective Studies
/
Proton Pumps
/
Quinolones
/
Alanine
/
2-Pyridinylmethylsulfinylbenzimidazoles
/
Proton Pump Inhibitors
Type of study:
Observational study
Limits:
Animals
/
Humans
Language:
Korean
Journal:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS